Halozyme Therapeutics (HALO) Net Income towards Common Stockholders Growth (1y) (2011 - 2026)
Halozyme Therapeutics (HALO) Net Income towards Common Stockholders Growth (1y) (2011 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
814,307.08 Bn |
814,307.05 Bn |
- |
- |
| 2 |
Belite Bio |
55,320.00 Bn |
55,320.00 Bn |
- |
-88.68% |
| 3 |
Quantum Biopharma |
17,149.72 Bn |
17,149.72 Bn |
- |
-58.11% |
| 4 |
Legend Biotech |
3,590.00 Bn |
3,589.71 Bn |
242.10 Mn |
104.24% |
| 5 |
Akari Therapeutics |
1,650.72 Bn |
1,650.72 Bn |
- |
-290.15% |
| 6 |
Evaxion A |
1,522.09 Bn |
1,522.07 Bn |
- |
-129.68% |
| 7 |
Psyence Biomedical |
229.39 Bn |
229.38 Bn |
- |
-230.18% |
| 8 |
Vertex Pharmaceuticals |
113.09 Bn |
105.85 Bn |
2.59 Bn |
59.59% |
| 9 |
Abivax |
90.15 Bn |
90.15 Bn |
- |
- |
| 10 |
Halozyme Therapeutics |
8.24 Bn |
7.92 Bn |
297.47 Mn |
27.06% |
| Date | Value |
|---|
| Mar 31, 2026 |
27.06% |
| Dec 31, 2025 |
-203.34% |
| Sep 30, 2025 |
27.92% |
| Jun 30, 2025 |
77.10% |
| Mar 31, 2025 |
53.72% |
| Dec 31, 2024 |
60.46% |
| Sep 30, 2024 |
67.42% |
| Jun 30, 2024 |
24.74% |
| Mar 31, 2024 |
93.92% |
| Dec 31, 2023 |
47.98% |
| Sep 30, 2023 |
32.78% |
| Jun 30, 2023 |
229.53% |
| Mar 31, 2023 |
-34.09% |
| Dec 31, 2022 |
-13.58% |
| Sep 30, 2022 |
-71.54% |
| Jun 30, 2022 |
-75.20% |
| Mar 31, 2022 |
115.48% |
| Dec 31, 2021 |
-8.74% |
| Sep 30, 2021 |
498.19% |
| Jun 30, 2021 |
254.25% |
